Skip to content

Tipranavir receives US marketing approval

TMC114 expanded access programme announced: regulatory approval to be sought early next year

BHIVA issues draft 2005 treatment guidelines, calls for comments by May 3rd

Benefits of genotypic testing confirmed in French clinic study

Small number of UK HIV-positive patients at risk of exhausting treatment options

Tipranavir superior to other PIs in detailed resistance analysis

TMC114 appears to be strong PI option for salvage therapy

Investigational NNRTI TMC278 swiftly cuts viral load in treatment-naive patients

Addition of capravirine to a three-drug regimen not beneficial in patients with NNRTI resistance